MATHEMATICAL MODEL OF IMMUNOTHERAPY RESPONSE TO ANTIBODIES AS A TREATMENT FOR CANCER

被引:0
|
作者
Simbawa, Eman [1 ]
Alharbi, Sara [1 ]
Aljohani, Jawaher [1 ]
Abosamra, Hala [1 ]
Aboushoushah, Samia [2 ]
Cristini, Vittorio [3 ]
机构
[1] King Abdulaziz Univ, Dept Math, Fac Sci, Jeddah 21589, Saudi Arabia
[2] King Abdulaziz Univ, Phys Dept, Fac Sci, Jeddah 21589, Saudi Arabia
[3] Houston Methodist Res Inst, Math Med Program, Houston, TX 77030 USA
关键词
antibodies; cancer; drug delivery; immunotherapy; mathematical modeling; MONOCLONAL-ANTIBODIES; THERAPY;
D O I
10.28919/cmbn/4570
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Immunotherapy is a significant cancer treatment as it uses the body's natural immune system to fight cancer. To help boost the immune system, monoclonal antibodies (MABs) are used as they bind to cancer cells helping the immune system recognize these cells. In this paper, we present a mathematical model of nonlinear partial differential equations describing the interaction between the immune cells, MABs, and cancer cells. After nondimensionalizing the model, we analyzed the long-term behavior and found later that it is consistent with the numerical results. Then, we calculated the numerical solutions of the model with different values of the parameters (relative growth rate of cancer cells and the number of immune cells that are removed after killing a cancer cell) to determine the values that help increase the effectiveness of the treatment. We have considered the continuous delivery of antibodies over a certain period of time. These simulations showed that immune cells will eradicate cancer if the number of immune cells that are removed after killing a cancer cell is less than one. However, if each immune cell kills only one cancer cell, then the treatment reduces the cancer to a steady state or almost a steady state. On the other hand, if the relative growth rate of cancer cells is very small and each cancer cell needs more than one immune cell to kill it, then again, we get a steady state for cancer. However, if the relative growth rate is not small, then the cancer will grow after an initial decrease. This study could be implemented into a clinical trial with different delivery protocols of the drug to improve cancer treatment.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [21] A mathematical prognosis model for pancreatic cancer patients receiving immunotherapy
    Li, Xuefang
    Xu, Jian-Xin
    JOURNAL OF THEORETICAL BIOLOGY, 2016, 406 : 42 - 51
  • [22] Mathematical model for IL-2-based cancer immunotherapy
    Dixon, Megan
    Phan, Tuan Anh
    Dallon, J. C.
    Tian, Jianjun Paul
    MATHEMATICAL BIOSCIENCES, 2024, 372
  • [23] Numerical Simulation of a Mathematical Model of Combination of Immunotherapy and Chemotherapy of Cancer
    Wei, Hsiu-Chuan
    Hwang, Shin-Feng
    Chen, Yuh-Yih
    Chen, Tze-Jang
    11TH INTERNATIONAL CONFERENCE OF NUMERICAL ANALYSIS AND APPLIED MATHEMATICS 2013, PTS 1 AND 2 (ICNAAM 2013), 2013, 1558 : 2080 - 2082
  • [24] Circulating biomarkers of response to immunotherapy in cancer treatment
    Del Re, Marzia
    Gianfilippo, Giulia
    Crucitta, Stefania
    Addeo, Alfredo
    van Schaik, Ron H. N.
    Danesi, Romano
    PHARMACOGENOMICS, 2019, 20 (18) : 1247 - 1249
  • [25] A mathematical model of the metastatic bottleneck predicts patient outcome and response to cancer treatment
    Szczurek, Ewa
    Krueger, Tyll
    Klink, Barbara
    Beerenwinkel, Niko
    PLOS COMPUTATIONAL BIOLOGY, 2020, 16 (10)
  • [26] A Mathematical Model of Cancer Treatment by Radiotherapy
    Liu, Zijian
    Yang, Chenxue
    COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2014, 2014
  • [27] A mathematical model of the effector cell response to cancer
    Allison, E
    Colton, AD
    Gorman, AD
    Kurt, R
    Shainheit, M
    MATHEMATICAL AND COMPUTER MODELLING, 2004, 39 (11-12) : 1313 - 1327
  • [28] Monoclonal antibodies in cancer immunotherapy
    Ilgin Kimiz-Gebologlu
    Sultan Gulce-Iz
    Cigir Biray-Avci
    Molecular Biology Reports, 2018, 45 : 2935 - 2940
  • [29] Immunotherapy of cancer by trifunctional antibodies
    Lindhofer, Horst
    INFLAMMATION RESEARCH, 2007, 56 : S147 - S147
  • [30] Bispecific antibodies in cancer immunotherapy
    Rader, Christoph
    CURRENT OPINION IN BIOTECHNOLOGY, 2020, 65 : 9 - 16